

Amendments to the Claims:

1. (Currently amended) A method of treatment of condylomata acuminata in humans ~~a disease condition caused by papilloma virus~~, which comprises:
applying ~~a treatment dose of~~ Bacillus Calmette-Guerin (BCG) to the ~~an~~ area of infection.

2. and 3. (Cancelled)

4. (Currently amended) The method of claim 1 which comprises applying BCG ~~wherein the disease condition is~~ external and intraurethral condylomata acuminata in humans.

5. to 7. (Cancelled)

8. (Currently amended) The method of claim 1 which comprises applying BCG in ~~wherein from about 1 to about 30 treatments of the infection time interval from about 1 to about 30 days between treatments of more than one and using an~~ the individual treatment dosage of is from about 1 to about 500 mg of the BCG, wherein said applications are made at time intervals from about 1 to about 30 days for applications more than one.

9. (Currently amended) The method of claim 1 which comprises performing is ~~preceded by~~ ablative surgery of the ~~region of~~ infection prior to said applying BCG.

10. (Original) The method of claim 9 wherein said ablative surgery is effected by laser

11. (Currently amended) The method of claim 1 which comprises formulating ~~wherein said BCG is formulated with a keratolytic agent for topical application to the area of infection, and then topically applying said BCG to the infection.~~

12. (Currently amended) The method of claim 11 which comprises formulating ~~wherein said BCG is formulated with a~~ said keratolytic agent ~~as a cream for~~

adherent application to the area of infection, and then adherently applying said BCG to the infection.

13. (Currently amended) The method of claim 1 which comprises formulating wherein said BCG is formulated with powdered salicylic acid as an adherent cream for application to the area of infection, and then adherently applying said BCG to the infection.

14. (Currently amended) The method of claim 13 which comprises formulating said BCG with wherein said salicylic acid is present in an amount of about 0.1 to about 50 wt% of the resulting formulation composition prior to said applying BCG to the infection.

15. (Currently amended) The method of claim 14 which comprises formulating said BCG wherein said salicylic acid is present in an amount of about 1 to about 10 wt% of the resulting formulation composition prior to applying BCG to the infection.

16. (Currently amended) A therapeutic composition for the treatment of condylomata acuminata ~~a disease condition caused by papilloma virus~~, comprising a treatment dose of Bacillus Calmette-Guerin (BCG) formulated with a keratolytic agent for topical application to the ~~an area of~~ infection.

17. to 19. (Cancelled)

20. (Previously amended) The composition of claim 16 wherein said keratolytic agent is powdered salicylic acid.

21. (Original) The composition of claim 20 wherein said salicylic acid is present in an amount of from about 0.1 to about 50 wt% of the composition.

22. (Previously amended) The composition of claim 21 wherein said salicylic acid is present in an amount of about 1 to about 10 wt% of the composition.

23. (Original) The composition of claim 16 which is formulated as a cream for adherent application to the region of infection.

Application No. 09/674,172

4

24. and 25. (Cancelled)